SE457505B - Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning - Google Patents

Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning

Info

Publication number: SE457505B
Authority: SE; Sweden
Prior art keywords: pharmaceutical composition; layer; active substance; copolymer; amount
Prior art date: 1984-01-10

Application number

SE8400085A

Other languages

English (en)

Swedish (sv)

Other versions

SE8400085L (sv

SE8400085D0 (sv

Inventor

C H Appelgren

C Eskilsson

Original Assignee

Lejus Medical Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-01-10

Filing date

1984-01-10

Publication date

1989-01-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20354249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE457505(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1984-01-10 Publication of SE8400085D0 publication Critical patent/SE8400085D0/xx

1984-01-10 Priority to SE8400085A priority Critical patent/SE457505B/sv

1984-01-10 Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab

1985-01-08 Priority to DE8888850123T priority patent/DE3586206T2/de

1985-01-08 Priority to DE8585850007T priority patent/DE3572767D1/de

1985-01-08 Priority to EP88850123A priority patent/EP0293347B1/de

1985-01-08 Priority to EP85850007A priority patent/EP0148811B1/de

1985-01-08 Priority to AT88850123T priority patent/ATE77077T1/de

1985-01-08 Priority to AT85850007T priority patent/ATE46080T1/de

1985-01-10 Priority to US06/690,197 priority patent/US4780318A/en

1985-07-11 Publication of SE8400085L publication Critical patent/SE8400085L/xx

1986-01-17 Priority to SE8600202A priority patent/SE462529B/sv

1988-03-25 Priority to US07/172,897 priority patent/US5001161A/en

1989-01-09 Publication of SE457505B publication Critical patent/SE457505B/sv

1990-09-28 Priority to US07/590,237 priority patent/US5081154A/en

1995-01-09 Priority to SG2295A priority patent/SG2295G/en

1995-02-23 Priority to HK24995A priority patent/HK24995A/en

1996-07-17 Priority to LV960257A priority patent/LV5814B4/xx

Links

238000000034 method Methods 0.000 title claims description 4
239000008203 oral pharmaceutical composition Substances 0.000 title claims 2
238000002360 preparation method Methods 0.000 title claims 2
239000012528 membrane Substances 0.000 claims description 23
239000008187 granular material Substances 0.000 claims description 22
239000013543 active substance Substances 0.000 claims description 20
238000009792 diffusion process Methods 0.000 claims description 20
239000002245 particle Substances 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 15
239000001856 Ethyl cellulose Substances 0.000 claims description 13
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 13
229920001249 ethyl cellulose Polymers 0.000 claims description 13
235000019325 ethyl cellulose Nutrition 0.000 claims description 13
229920001577 copolymer Polymers 0.000 claims description 10
229920006318 anionic polymer Polymers 0.000 claims description 9
-1 methacrylate methyl methacrylate methyl methacrylate methyl methacrylate Chemical compound 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 6
229960003883 furosemide Drugs 0.000 claims description 6
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical group C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 6
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 5
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
239000011248 coating agent Substances 0.000 claims description 4
238000000576 coating method Methods 0.000 claims description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
229920000609 methyl cellulose Polymers 0.000 claims description 4
239000001923 methylcellulose Substances 0.000 claims description 4
235000010981 methylcellulose Nutrition 0.000 claims description 4
229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
229960001404 quinidine Drugs 0.000 claims description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
150000007513 acids Chemical class 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
150000004665 fatty acids Chemical class 0.000 claims description 3
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
AKYHKWQPZHDOBW-VJAUXQICSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-VJAUXQICSA-N 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 2
229960004963 mesalazine Drugs 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
229960003712 propranolol Drugs 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 6
MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 claims 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
239000000470 constituent Substances 0.000 claims 1
210000001035 gastrointestinal tract Anatomy 0.000 claims 1
229940050410 gluconate Drugs 0.000 claims 1
229940102838 methylmethacrylate Drugs 0.000 claims 1
239000000178 monomer Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract 2
RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 abstract 1
229960000939 metoprolol succinate Drugs 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
210000004051 gastric juice Anatomy 0.000 description 10
239000008363 phosphate buffer Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
230000002378 acidificating effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
ZHNFLHYOFXQIOW-AHSOWCEXSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-AHSOWCEXSA-N 0.000 description 3
229920003134 Eudragit® polymer Polymers 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
SSONCJTVDRSLNK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;hydrochloride Chemical compound Cl.CC(=C)C(O)=O SSONCJTVDRSLNK-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000004927 fusion Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940073584 methylene chloride Drugs 0.000 description 2
230000035699 permeability Effects 0.000 description 2
BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
229920003139 Eudragit® L 100 Polymers 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002184 metal Substances 0.000 description 1
HTEAGOMAXMOFFS-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.COC(=O)C(C)=C HTEAGOMAXMOFFS-UHFFFAOYSA-N 0.000 description 1
QPNHNCISNUAHNE-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;trimethylazanium;chloride Chemical compound [Cl-].C[NH+](C)C.COC(=O)C(C)=C QPNHNCISNUAHNE-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960002005 metoprolol fumarate Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229920000120 polyethyl acrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 description 1
229960002693 quinidine bisulfate Drugs 0.000 description 1
229960002454 quinidine gluconate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE8400085A 1984-01-10 1984-01-10 Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning SE457505B (sv)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
SE8400085A SE457505B (sv)	1984-01-10	1984-01-10	Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
DE8888850123T DE3586206T2 (de)	1984-01-10	1985-01-08	Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung.
DE8585850007T DE3572767D1 (en)	1984-01-10	1985-01-08	Pharmaceutical composition
EP88850123A EP0293347B1 (de)	1984-01-10	1985-01-08	Metoprololsuccinat und dieses enthaltende pharmazeutische Zusammensetzung
EP85850007A EP0148811B1 (de)	1984-01-10	1985-01-08	Pharmazeutische Komposition
AT88850123T ATE77077T1 (de)	1984-01-10	1985-01-08	Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung.
AT85850007T ATE46080T1 (de)	1984-01-10	1985-01-08	Pharmazeutische komposition.
US06/690,197 US4780318A (en)	1984-01-10	1985-01-10	Oral pharmaceutical composition
SE8600202A SE462529B (sv)	1984-01-10	1986-01-17	Metoprololsuccinat samt farmaceutisk komposition innehaallande detsamma
US07/172,897 US5001161A (en)	1984-01-10	1988-03-25	Pharmaceutical composition comprising metroprolol succinate
US07/590,237 US5081154A (en)	1984-01-10	1990-09-28	Metoprolol succinate
SG2295A SG2295G (en)	1984-01-10	1995-01-09	Metropolol succinate and pharmaceutical composition containing it
HK24995A HK24995A (en)	1984-01-10	1995-02-23	Metoprolol succinate and pharmaceutical composition containing it
LV960257A LV5814B4 (lv)	1984-01-10	1996-07-17	Metoprolola sukcinats

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8400085A SE457505B (sv)	1984-01-10	1984-01-10	Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning

Publications (3)

Publication Number	Publication Date
SE8400085D0 SE8400085D0 (sv)	1984-01-10
SE8400085L SE8400085L (sv)	1985-07-11
SE457505B true SE457505B (sv)	1989-01-09

Family

ID=20354249

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SE8400085A SE457505B (sv)	1984-01-10	1984-01-10	Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
SE8600202A SE462529B (sv)	1984-01-10	1986-01-17	Metoprololsuccinat samt farmaceutisk komposition innehaallande detsamma

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SE8600202A SE462529B (sv)	1984-01-10	1986-01-17	Metoprololsuccinat samt farmaceutisk komposition innehaallande detsamma

Country Status (7)

Country	Link
US (2)	US4780318A (de)
EP (2)	EP0293347B1 (de)
AT (2)	ATE77077T1 (de)
DE (2)	DE3586206T2 (de)
HK (1)	HK24995A (de)
SE (2)	SE457505B (de)
SG (1)	SG2295G (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57500432A (de) *	1980-03-20	1982-03-11
US4960765A (en) *	1980-03-20	1990-10-02	Farmaceutisk Laboratorium Ferring A/S	Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS6261916A (ja) *	1985-09-12	1987-03-18	Fujisawa Pharmaceut Co Ltd	持続性製剤
SE455836B (sv)	1985-10-11	1988-08-15	Haessle Ab	Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
SE450087B (sv) *	1985-10-11	1987-06-09	Haessle Ab	Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4717567A (en) *	1985-11-25	1988-01-05	Eastman Kodak Company	Rumen-stable pellets
GB2186485B (en) *	1986-02-13	1988-09-07	Ethical Pharma Ltd	Slow release formulation
AU591248B2 (en) *	1986-03-27	1989-11-30	Kinaform Technology, Inc.	Sustained-release pharaceutical preparation
US5238686A (en) *	1986-03-27	1993-08-24	Kinaform Technology, Inc.	Sustained-release pharmaceutical preparation
EP0294493A4 (de) *	1986-12-25	1989-07-24	Teysan Pharmaceuticals Co Ltd	Langsamlösliches granulatkorn und daraus hergestelltes langwirkendes mischgranulat.
SE460945B (sv) *	1987-01-15	1989-12-11	Lejus Medical Ab	En multipel-unit-dos komposition av furosemid
US4789549A (en) *	1987-03-09	1988-12-06	Warner-Lambert Company	Sustained release dosage forms
SE460946B (sv) *	1987-03-16	1989-12-11	Lejus Medical Ab	En multipel-unit-dos komposition av kinidinglukonat
SE8703881D0 (sv) *	1987-10-08	1987-10-08	Haessle Ab	New pharmaceutical preparation
IL88083A (en) *	1987-11-06	1992-11-15	Tanabe Seiyaku Co	Controlled release pharmaceutical dosage form and its preparation
FR2624732B1 (fr) *	1987-12-21	1991-02-15	Synthelabo	Formulation pharmaceutique a liberation prolongee
US4971805A (en) *	1987-12-23	1990-11-20	Teysan Pharmaceuticals Co., Ltd.	Slow-releasing granules and long acting mixed granules comprising the same
FI101344B1 (fi) *	1988-03-31	1998-06-15	Tanabe Seiyaku Co	Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US4892739A (en) *	1988-04-25	1990-01-09	Ciba-Geigy Corporation	Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
FR2634376B1 (fr) *	1988-07-21	1992-04-17	Farmalyoc	Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
EP0352800A3 (de) *	1988-07-28	1991-05-08	Warner-Lambert Company	Wässerige Polymerdispersion eines Cellulose- und Acrylharzes und ihre Anwendung für die Herstellung von Arzneidosiereinheiten
US5296236A (en) *	1988-09-16	1994-03-22	Recordati S.A., Chemical And Pharmaceutical Company	Controlled release therapeutic system for a liquid pharmaceutical formulations
GB8913889D0 (en) *	1989-06-16	1989-08-02	May & Baker Ltd	New compositions of matter
GB8915137D0 (en) *	1989-06-30	1989-08-23	Inmos Ltd	Message routing
US5422881A (en) *	1989-06-30	1995-06-06	Inmos Limited	Message encoding
IT1246382B (it) *	1990-04-17	1994-11-18	Eurand Int	Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
EP0458751A1 (de) *	1990-05-25	1991-11-27	Warner-Lambert Company	System zur Freisetzung von cyclischen Aminosäuren mit verbessertem Geschmack, Struktur und Komprimierbarkeit
ES2053333T3 (es) *	1990-07-26	1994-07-16	Searle & Co	Sistema polimerico para la administracion de farmacos.
US5316772A (en) *	1990-12-19	1994-05-31	Solvay & Cie, S.A. (Societe Anonyme)	Bilayered oral pharmaceutical composition with pH dependent release
US6764697B1 (en) *	1991-06-27	2004-07-20	Alza Corporation	System for delaying drug delivery up to seven hours
EP0653935B1 (de) *	1992-08-05	2002-05-08	F.H. FAULDING & CO. LIMITED	Granulierte pharmazeutische zusammensetzung
DK0667148T3 (da) *	1992-11-06	2002-07-22	Hisamitsu Pharmaceutical Co	Peroralt farmaceutisk præparat, der udløses i den nedre del af mavetarmkanalen
US5358502A (en) *	1993-02-25	1994-10-25	Pfizer Inc	PH-triggered osmotic bursting delivery devices
ATE195252T1 (de) *	1993-04-23	2000-08-15	Novartis Erfind Verwalt Gmbh	Wirkstoffabgabevorrichtung mit gesteuerter freigabe
DE4329503A1 (de) *	1993-09-01	1995-03-02	Galenik Labor Freiburg Gmbh	Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en)	1993-09-01	2001-03-20	Novatis Ag	Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US6039975A (en) *	1995-10-17	2000-03-21	Hoffman-La Roche Inc.	Colon targeted delivery system
BR9612213A (pt) *	1995-12-21	1999-12-28	Ferring Farma Lab	Composição farmaceutica oralmente liberada modificada contendo 5-asa e método para o tratamento de doenças do instetino.
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) *	1997-01-29	1998-08-04	Poli Industria Chimica Spa	Methods for treating early morning pathologies
DE19732903A1 (de)	1997-07-30	1999-02-04	Falk Pharma Gmbh	Pellet-Formulierung zur Behandlung des Intestinaltraktes
DE19845358A1 (de)	1998-10-02	2000-04-06	Roehm Gmbh	Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
US6962717B1 (en)	1999-01-29	2005-11-08	Disphar International B.V.	Pharmaceutical compositions
WO2002018324A2 (en)	2000-08-29	2002-03-07	Nobex Corporation	Immunoregulatory compounds, derivatives thereof and their use
CA2359812C (en) *	2000-11-20	2004-02-10	The Procter & Gamble Company	Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6610326B2 (en)	2001-02-16	2003-08-26	Andrx Corporation	Divalproex sodium tablets
US20040105886A1 (en) *	2001-02-16	2004-06-03	Chih-Ming Chen	Divalproex sodium tablets
NZ527832A (en) *	2001-03-13	2006-03-31	Penwest Pharmaceuticals Co	Chronotherapeutic dosage forms
US8048924B2 (en)	2001-08-29	2011-11-01	Biocon Limited	Methods and compositions employing 4-aminophenylacetic acid compounds
SE0102887D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102886D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
SE0102888D0 (sv) *	2001-08-29	2001-08-29	Astrazeneca Ab	New formulation
US9358214B2 (en) *	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
US6500454B1 (en) *	2001-10-04	2002-12-31	Eurand Pharmaceuticals Ltd.	Timed, sustained release systems for propranolol
AR036797A1 (es)	2001-10-15	2004-10-06	Ferring Bv	Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
WO2003057166A2 (en) *	2002-01-07	2003-07-17	Pharmacia Corporation	Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
US7022342B2 (en)	2002-03-28	2006-04-04	Andrx Corporation, Inc.	Controlled release oral dosage form of beta-adrenergic blocking agents
CA2481091A1 (en) *	2002-04-05	2003-10-23	Penwest Pharmaceuticals Co.	Sustained release metoprolol formulations
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
WO2004069234A1 (en) *	2003-02-05	2004-08-19	Ipca Laboratories Limited	Pharmaceutical compositions and process of production thereof
CA2520197A1 (en)	2003-04-23	2004-11-04	Ferring B.V.	Sachet for a pharmaceutical composition
US7314640B2 (en) *	2003-07-11	2008-01-01	Mongkol Sriwongjanya	Formulation and process for drug loaded cores
US20050032879A1 (en) *	2003-08-07	2005-02-10	Temple Okarter	Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
EA200600598A1 (ru) *	2003-09-19	2006-08-25	Пенвест Фармасьютикалз Ко.	Лекарственные формы замедленного высвобождения
AU2004273958A1 (en) *	2003-09-19	2005-03-31	Penwest Pharmaceuticals Co.	Chronotherapeutic dosage forms
EP1547601A1 (de)	2003-12-23	2005-06-29	Ferring B.V.	Beschichtungsverfahren
MXPA06009054A (es) *	2004-02-11	2007-04-16	Athpharma Ltd	Composiciones cronoterapeuticas y metodos de su uso.
DK1773767T3 (en)	2004-07-07	2016-03-21	Biocon Ltd	Synthesis of azo bound in immune regulatory relations
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
NZ728442A (en)	2004-10-21	2018-05-25	Adare Pharmaceuticals Inc	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
JP2008525313A (ja)	2004-12-27	2008-07-17	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬の安定化方法
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
US20070087056A1 (en) *	2005-08-09	2007-04-19	Claudia Guthmann	Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070053983A1 (en) *	2005-09-06	2007-03-08	Girish Jain	Extended release compositions of metoprolol succinate
EP1971570A2 (de) *	2005-12-23	2008-09-24	Medichem, S.A.	Verfahren zur herstellung von metoprolol und dessen salzen
US20090028944A1 (en) *	2007-07-16	2009-01-29	Balaji Sathurappan	Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) *	2007-08-02	2009-02-05	Mutual Pharmaceutical Company, Inc.	Mesalamine Formulations
US20090062191A1 (en) *	2007-08-29	2009-03-05	Kiel Laboratories, Inc.	Composition for maintaining gastrointestinal homeostasis
US20090214665A1 (en) *	2008-02-26	2009-08-27	Lai Felix S	Controlled Release Muscarinic Receptor Antagonist Formulation
CN102238868A (zh)	2008-10-03	2011-11-09	福尔克博士药物有限责任公司	使用颗粒状5-氨基水杨酸治疗肠病的组合物和方法
DK2255791T3 (da)	2009-04-03	2012-03-05	Zaklady Farmaceutyczne Polpharma Sa	Forlænget-frigivelse-farmaceutisk sammensætning omfattende metoprololsuccinat
CN102008457B (zh) *	2009-09-04	2014-04-02	北京天衡药物研究院	酒石酸美托洛尔骨架缓释片
AU2010325746B2 (en)	2009-12-02	2016-02-25	Adare Pharmaceuticals S.R.L.	Fexofenadine microcapsules and compositions containing them
IL210279A0 (en)	2009-12-25	2011-03-31	Dexcel Pharma Technologies Ltd	Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2099402A (en) *	1934-01-17	1937-11-16	Pratt Food Company	Pill or tablet
DE1228757B (de) *	1962-06-28	1966-11-17	Haessle Ab	Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
DE1204363B (de) *	1963-09-10	1965-11-04	Hoffmann La Roche	Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
US3483221A (en) *	1964-09-10	1969-12-09	Ciba Geigy Corp	1 - (isopropylamino)-2-hydroxy-3-(alkenyloxyphenoxy) - propanes and the salts thereof
NL130749C (de) *	1964-09-10
AT270071B (de) *	1966-08-12	1969-04-10	Roehm & Haas Gmbh	Dragierlack für Arzneiformen
US3629237A (en) *	1968-09-12	1971-12-21	Shinetsu Chemical Co	Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
SE384853B (sv) *	1972-04-04	1976-05-24	Haessle Ab	Forfarande for framstellning av nya aminer
SE354851B (de) *	1970-02-18	1973-03-26	Haessle Ab
US3909444A (en) *	1971-08-05	1975-09-30	Ncr Co	Microcapsule
US4145442A (en) *	1972-04-04	1979-03-20	Aktiebolaget Hassle	Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
IL43853A0 (en) *	1973-02-16	1974-03-14	Sparamedica Ag	Pharmaceutical compositions and their manufacture
JPS5518694B2 (de) *	1973-04-02	1980-05-21
GB1413186A (en) *	1973-06-27	1975-11-12	Toyo Jozo Kk	Process for encapsulation of medicaments
SE385693B (sv) *	1973-10-08	1976-07-19	Haessle Ab	Forfarande for framstellning av nya aminer
SE388849B (sv) *	1974-02-14	1976-10-18	Haessle Ab	Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan
JPS5512411B2 (de) *	1974-03-12	1980-04-02
ZA754241B (en) *	1974-11-01	1976-06-30	Haessle Ab	New amines
SE402765B (sv) *	1975-06-04	1978-07-17	Haessle Ab	Forfarande for framstellning av en ny hjertaktiv forening
SE418247B (sv) *	1975-11-17	1981-05-18	Haessle Ab	Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
DE2645710C2 (de) *	1976-10-09	1985-06-27	Merck Patent Gmbh, 6100 Darmstadt	Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4218433A (en) *	1977-03-03	1980-08-19	Nippon Kayaku Kabushiki Kaisha	Constant-rate eluting tablet and method of producing same
GB1576376A (en) *	1977-03-30	1980-10-08	Benzon As Alfred	Multiple-unit drug dose
DE2905134A1 (de) *	1978-02-17	1979-08-23	Degussa	Neue acylierte aminoalkyl-cyanoguanidine mit einem heterocyclischen rest
SE426548B (sv) *	1978-12-05	1983-01-31	Haessle Ab	Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
GB2051574B (en) *	1979-05-10	1984-01-18	Kyoto Pharma Ind	Adjuvant for promoting absorption of pharmacologically active substances through the rectum
FR2471186A1 (fr) *	1979-12-10	1981-06-19	Roussel Uclaf	Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv) *	1980-05-21	1981-11-22	Haessle Ab	En farmaceutisk beredning med forbettrade utlosningsegenskap
JPS57171428A (en) *	1981-04-13	1982-10-22	Sankyo Co Ltd	Preparation of coated solid preparation
EP0064485B1 (de) *	1981-04-27	1985-07-24	Aktiebolaget Hässle	Pharmazeutisches Präparat
ZA825384B (en) *	1981-07-31	1983-05-25	Tillott J B Ltd	Orally administrable pharmaceutical compositions
DK150008C (da) *	1981-11-20	1987-05-25	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
DE3208791A1 (de) *	1982-03-11	1983-09-22	Röhm GmbH, 6100 Darmstadt	Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
EP0094117A3 (de) *	1982-05-06	1984-08-01	The Procter & Gamble Company	Therapeutische Granulate
US4415547A (en) *	1982-06-14	1983-11-15	Sterling Drug Inc.	Sustained-release pharmaceutical tablet and process for preparation thereof
JPS5920219A (ja) *	1982-07-26	1984-02-01	Shin Etsu Chem Co Ltd	腸溶性コ−テイング製剤の製造方法
US4578075A (en) *	1982-12-20	1986-03-25	Alza Corporation	Delivery system housing a plurality of delivery devices
US4681583A (en) *	1982-12-20	1987-07-21	Alza Corporation	System for dispersing drug in biological environment
JPS59193831A (ja) *	1983-04-18	1984-11-02	Sankyo Co Ltd	腸溶性製剤の製造法
US4627850A (en) *	1983-11-02	1986-12-09	Alza Corporation	Osmotic capsule
AU565354B2 (en) *	1983-11-14	1987-09-10	Bio-Mimetics Inc.	Bioadhesive compositions and methods of treatment therewith
US4623588A (en) *	1984-02-06	1986-11-18	Biotek, Inc.	Controlled release composite core coated microparticles
DE3405378A1 (de) *	1984-02-15	1985-08-22	Röhm GmbH, 6100 Darmstadt	Arzneimittelueberzug

1984
- 1984-01-10 SE SE8400085A patent/SE457505B/sv not_active IP Right Cessation
1985
- 1985-01-08 AT AT88850123T patent/ATE77077T1/de not_active IP Right Cessation
- 1985-01-08 DE DE8888850123T patent/DE3586206T2/de not_active Expired - Lifetime
- 1985-01-08 AT AT85850007T patent/ATE46080T1/de not_active IP Right Cessation
- 1985-01-08 EP EP88850123A patent/EP0293347B1/de not_active Expired
- 1985-01-08 DE DE8585850007T patent/DE3572767D1/de not_active Expired
- 1985-01-08 EP EP85850007A patent/EP0148811B1/de not_active Expired
- 1985-01-10 US US06/690,197 patent/US4780318A/en not_active Expired - Lifetime
1986
- 1986-01-17 SE SE8600202A patent/SE462529B/sv not_active IP Right Cessation
1988
- 1988-03-25 US US07/172,897 patent/US5001161A/en not_active Expired - Lifetime
1995
- 1995-01-09 SG SG2295A patent/SG2295G/en unknown
- 1995-02-23 HK HK24995A patent/HK24995A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
SE8600202L (sv)	1986-01-17
DE3572767D1 (en)	1989-10-12
US4780318A (en)	1988-10-25
SE462529B (sv)	1990-07-09
DE3586206D1 (de)	1992-07-16
US5001161A (en)	1991-03-19
ATE77077T1 (de)	1992-06-15
SG2295G (en)	1995-06-16
EP0293347A1 (de)	1988-11-30
ATE46080T1 (de)	1989-09-15
SE8400085L (sv)	1985-07-11
SE8400085D0 (sv)	1984-01-10
EP0148811A1 (de)	1985-07-17
HK24995A (en)	1995-03-03
EP0148811B1 (de)	1989-09-06
DE3586206T2 (de)	1992-12-24
SE8600202D0 (sv)	1986-01-17
EP0293347B1 (de)	1992-06-10

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8400085-0

Effective date: 19920806

Format of ref document f/p: F

Publication	Publication Date	Title
SE457505B (sv)	1989-01-09	Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
FI113743B (fi)	2004-06-15	Menetelmä säädetysti vapauttavan valmisteen valmistamiseksi
EP1117387B1 (de)	2005-01-12	Überzogene arzneiformen mit kontrollierter wirkstoffabgabe
JP4172917B2 (ja)	2008-10-29	急速に効果を発揮し且つ効果的な血漿薬物濃度が急速に低下する制御放出性製剤
KR940000098B1 (ko)	1994-01-05	유효 화합물을 서서히 방출하는 신규 제제의 제조방법
JP3902229B2 (ja)	2007-04-04	結腸デリバリー用の、多腸溶ポリマー被覆物を有する医薬投与形態
US5229135A (en)	1993-07-20	Sustained release diltiazem formulation
US5175003A (en)	1992-12-29	Dual mechanism controlled release system for drug dosage forms
CN1404389B (zh)	2011-08-24	时控脉冲给药系统
DK174949B1 (da)	2004-03-22	Formuleringer med forlænget frigivelse og deres fremstilling
SE455836B (sv)	1988-08-15	Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
JP2004512296A (ja)	2004-04-22	メチルフェニデート改変放出製剤
BR9914977B1 (pt)	2014-03-11	Composição multiparticulada de liberação modificada
BG65398B1 (bg)	2008-06-30	Ентерично покрит фармацевтичен състав и метод за получаване
JP2004323536A (ja)	2004-11-18	血漿中の薬物レベルの初期上昇速度が急速な２４時間経口オピオイド製剤の投与による、疼痛の治療方法
CA2071319A1 (en)	1992-12-18	Oral diclofenac preparation
RS59061B1 (sr)	2019-08-30	Farmaceutska kompozicija
SE447871B (sv)	1986-12-22	Farmaceutisk komposition med lang utsondringstid innefattande pinacidil i minst tva olika typer av pelletar
US6635277B2 (en)	2003-10-21	Composition for pulsatile delivery of diltiazem and process of manufacture
US6994873B2 (en)	2006-02-07	Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
US7041317B2 (en)	2006-05-09	Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino] pyrimidine trihydrochloride as active ingredient
EP0796089A1 (de)	1997-09-24	Diltiazemhydrochlorid-formulierung
KR940008415B1 (ko)	1994-09-14	코팅 막과 그로부터 제조된 조성물
JPS615010A (ja)	1986-01-10	水素添加麦角アルカロイド徐放性製剤及びその製法
FI102455B (fi)	1998-12-15	Menetelmä oraalisen farmaseuttisen moniyksikköformulaation valmistamis eksi